A recent study published in the journal Nature Medicine has highlighted the significant health benefits of semaglutide for individuals with chronic kidney disease (CKD) and type 2 diabetes (T2D). The research examined the effects of semaglutide both with and without the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors, known for their cardiovascular benefits.
This groundbreaking study, titled “Evaluate Renal Function with Semaglutide Once Weekly” (FLOW), is the first to focus specifically on kidney outcomes for patients with CKD and T2D. While previous trials involving SGLT2 inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists have shown cardiovascular benefits for high-risk diabetes patients, this study uniquely highlights the dual benefits for both kidney and heart health.
Researchers randomized over 3,500 patients with CKD and T2D to receive either semaglutide once weekly or a placebo. Participants included adults over 18 years old with renal impairment and were already receiving treatment with renin-angiotensin-aldosterone inhibitors.
Exclusions were made for patients with hypersensitivity to the trial products, recent stroke or myocardial infarction, uncontrolled diabetic retinopathy, hereditary kidney diseases, recent GLP-1 receptor agonist use, and other conditions. The primary outcome measured was a composite of a 50% reduction in estimated glomerular filtration rate (eGFR) sustained for at least 28 days, or death due to cardiovascular or kidney-related causes. Secondary outcomes included the rate of kidney function loss, major adverse cardiovascular events (MACEs), and all-cause mortality. Cox proportional hazard models were used to analyze the time-to-event data.
Over a median follow-up period of 3.4 years, the study revealed significant benefits of semaglutide on both kidney and cardiovascular health. Among those using SGLT2 inhibitors at baseline, 14.8% of semaglutide recipients experienced primary outcome events, compared to 13.9% in the placebo group. For non-users, the figures were 19.5% for semaglutide and 24.9% for placebo recipients. In the SGLT2 inhibitor subgroup, kidney-specific outcomes occurred in 11.6% of semaglutide recipients versus 9.9% of placebo recipients. Among non-users, 12.5% of semaglutide patients experienced kidney-specific outcomes, compared to 15.6% of placebo recipients. Major adverse cardiovascular events were less frequent in the semaglutide group, irrespective of SGLT2 inhibitor use. All-cause mortality was also lower in the semaglutide group, with consistent results across both subgroups.
These findings underscore the potential of semaglutide as a critical treatment for patients with CKD and T2D, offering robust protection against both kidney and heart complications. The study suggests that combining semaglutide with SGLT2 inhibitors could further enhance clinical outcomes, although this specific combination requires further investigation.
Dr. Caroline Ruda, a leading researcher in the study, emphasized the importance of these results: “The FLOW trial demonstrates the dual benefits of semaglutide, significantly improving kidney and cardiovascular outcomes. This could revolutionize the treatment approach for patients with chronic kidney disease and type 2 diabetes.”
The FLOW trial marks a significant advancement in the treatment of CKD and T2D, showcasing semaglutide’s profound impact on kidney and heart health. As healthcare providers consider these findings, the potential for improved patient outcomes through the use of semaglutide, especially in combination with SGLT2 inhibitors, becomes increasingly apparent.
Related topics:
- Health Advisory Issued Amid Tourism Surge and Junior Doctors’ Strike
- Select US Surgeon General Declares Gun Violence a Public Health Crisis US
- Health Experts Emphasize Prevention in Reimagining Heart Care
